Literature DB >> 1424667

Anti-inflammatory therapy and outcome in a guinea pig model of Pseudomonas keratitis.

C Ohadi1, K L Litwin, H Moreira, S Kwitko, W J Gauderman, D C Gritz, A Gwon, R Jones, P J McDonnell.   

Abstract

Corneal scarring as a consequence of bacterial keratitis is an important cause of visual loss and a major indication for penetrating keratoplasty. Anti-inflammatory agents might be useful in this condition for limiting corneal damage, but benefit from adjunctive anti-inflammatory therapy has never been demonstrated. In this limited pilot study, we compared the effect on clinical outcome of treating Pseudomonas keratitis in guinea pigs with prednisolone (a corticosteroid), flurbiprofen (a cyclo-oxygenase inhibitor), nordihydroguaiaretic acid (a lipoxygenase inhibitor), and a leukotriene antagonist, SKF104353 [R-(R*, S*)]-beta-[(2-carboxyethyl) thio-alpha-hydroxy-2-(8-phenyloctyl) benzenepropanoic acid, zinc salt]. None of the anti-inflammatory agents prevented sterilization of ulcers with antibiotic (ofloxacin) therapy. Therapy with the leukotriene antagonist appeared to reduce infiltrate size more quickly and produce a more rapid reduction in lesion size, but the differences were not statistically significant. Sample size calculations suggest that very large numbers of animals would be required to prove efficacy. The role of anti-inflammatory agents in reducing the stromal destruction caused by bacterial keratitis remains controversial.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1424667     DOI: 10.1097/00003226-199209000-00007

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  8 in total

1.  The steroids for corneal ulcers trial: study design and baseline characteristics.

Authors:  Muthiah Srinivasan; Jeena Mascarenhas; Revathi Rajaraman; Meenakshi Ravindran; Prajna Lalitha; David V Glidden; Kathryn J Ray; Kevin C Hong; Catherine E Oldenburg; Salena M Lee; Michael E Zegans; Stephen D McLeod; Thomas M Lietman; Nisha R Acharya
Journal:  Arch Ophthalmol       Date:  2011-10-10

2.  The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial.

Authors:  Muthiah Srinivasan; Jeena Mascarenhas; Revathi Rajaraman; Meenakshi Ravindran; Prajna Lalitha; Kieran S O'Brien; David V Glidden; Kathryn J Ray; Catherine E Oldenburg; Michael E Zegans; John P Whitcher; Stephen D McLeod; Travis C Porco; Thomas M Lietman; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2013-10-01       Impact factor: 5.258

3.  Changing trends in the clinical course and outcome of bacterial keratitis at King Khaled Eye Specialist Hospital.

Authors:  Ali Al-Shehri; Sabah Jastaneiah; Michael D Wagoner
Journal:  Int Ophthalmol       Date:  2008-04-03       Impact factor: 2.031

4.  Age and therapeutic outcome of experimental Pseudomonas aeruginosa keratitis treated with ciprofloxacin, prednisolone, and flurbiprofen.

Authors:  J A Hobden; J M Hill; L S Engel; R J O'Callaghan
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

Review 5.  Pharmacokinetic considerations in the treatment of bacterial keratitis.

Authors:  M C Callegan; R J O'Callaghan; J M Hill
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

6.  Nocardia keratitis: clinical course and effect of corticosteroids.

Authors:  Prajna Lalitha; Muthiah Srinivasan; Revathi Rajaraman; Meenakshi Ravindran; Jeena Mascarenhas; Jeganathan Lakshmi Priya; Aileen Sy; Catherine E Oldenburg; Kathryn J Ray; Michael E Zegans; Stephen D McLeod; Thomas M Lietman; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2012-09-05       Impact factor: 5.258

Review 7.  Animal models of bacterial keratitis.

Authors:  Mary E Marquart
Journal:  J Biomed Biotechnol       Date:  2011-01-04

8.  The novel model: Experimental optical coherence tomography-guided anterior segment imaging chick embryo model.

Authors:  Resat Duman; Tolga Ertekin; Rahmi Duman; Esra Aslan; Mehmet Cem Sabaner; Ersan Cetinkaya
Journal:  Indian J Ophthalmol       Date:  2019-01       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.